Year All20252024202320222021202020192018201720162015201420122011 Nov 3, 2022 Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dial Nov 2, 2022 Ardelyx, Inc. Reports Employment Inducement Grants Oct 31, 2022 Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan Oct 27, 2022 Ardelyx to Report Third Quarter 2022 Financial Results on November 3, 2022 Oct 24, 2022 Ardelyx to Present Poster Presentations on IBSRELA® (tenapanor) for Adult Patients with IBS-C at the American College of Gastroenterology 2022 Annual Scientific Meeting Oct 20, 2022 Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022 Sep 30, 2022 Ardelyx, Inc. Reports Employment Inducement Grants Sep 6, 2022 Ardelyx to Participate in Upcoming Investor Conferences Aug 4, 2022 Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights Aug 2, 2022 Ardelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference